SOURCE: The Bedford Report

The Bedford Report

November 18, 2011 08:16 ET

Zalicus and Oncothyreon -- Low Valuations Reawaken Investor Enthusiasm

The Bedford Report Provides Equity Research on Zalicus & Oncothyreon

NEW YORK, NY--(Marketwire - Nov 18, 2011) - Despite disappointing third quarter results for some of biotechnology's up-and-coming stars, there is plenty of optimism in the industry. According to Lipper Inc. healthcare and biotechnology stock funds are up 17 percent this year and 35 percent over the past 12 months. Healthcare stocks underperformed during last year's market rally, and Andy Oh, research analyst and portfolio manager of the Fidelity Select Pharmaceuticals Fund argues that investors are embracing the "cheap valuations in health care stocks." The Bedford Report examines the outlook for companies in the biotechnology industry and provides equity research on Zalicus, Inc. (NASDAQ: ZLCS) and Oncothyreon Inc. (NASDAQ: ONTY). Access to the full company reports can be found at:

www.bedfordreport.com/ZLCS

www.bedfordreport.com/ONTY

The increase in M&A activity in the healthcare sector is yet another reason investors are once again taking a close look at biotech stocks. Michael Gregory, portfolio manager of the Highland Long/Short Health care Fund argues that "acquisitions are needed to fuel growth" as government intervention suppresses growth in larger firms. Moreover, Big Pharma companies are about to face the largest patent expiration cliff in the industry's history and will need to fill the gap of lost income.

The Bedford Report releases investment research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Zalicus is a biopharmaceutical company that discovers and develops novel treatments in the areas of pain, inflammation, oncology and infectious disease. During its most recent earnings announcement the company said patient enrollment in the SYNERGY Phase 2b clinical trial of "Synavive" for rheumatoid arthritis is on track with clinical sites actively recruiting subjects across the United States, Europe and Latin America.

Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. Cancer is projected to become the leading cause of death worldwide this year by the World Health Organisation, and has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information